Loading organizations...
§ Private Profile · Cleveland, OH, USA
Biotech company developing blood tests for early cancer detection, focused on IsoPSA prostate cancer diagnostics.
Based in Cleveland, Ohio, Cleveland Diagnostics is a clinical-stage biotechnology company that develops next-generation blood tests for early cancer detection using its proprietary IsoClear protein-analysis platform. The organization's flagship product, IsoPSA, is a diagnostic blood test designed to reduce unnecessary prostate biopsies, which is distributed nationally through a strategic commercial partnership with Quest Diagnostics. Operating with a workforce of approximately 60 employees under the leadership of Chief Executive Officer Michael Iskra, the precision oncology enterprise generates an estimated $20.3 million in annual revenue. To date, Cleveland Diagnostics has secured $109.1 million in total venture funding, including a recent $75 million financing round, to support the ongoing commercialization of its clinical portfolio and secure regulatory approvals from the United States FDA. The company was founded in 2013 by Arnon Chait and the Cleveland Clinic.
Cleveland Diagnostics has raised $92.4M across 2 funding rounds.
Cleveland Diagnostics has raised $92.4M in total across 2 funding rounds.
Cleveland Diagnostics has raised $92.4M in total across 2 funding rounds.
Cleveland Diagnostics's investors include Noel Jee, LYFE Capital, Eric A. Klein, MD.
Cleveland Diagnostics has raised $92.4M across 2 funding rounds. Most recently, it raised $75.0M Other Equity in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 17, 2024 | $75M Venture Round | Noel JEE | — | Announced |
| Feb 9, 2021 | $17.4M Series D | Lyfe Capital | Eric A. Klein, MD | Announced |